ReviewArchives of dermatological research2025
The evolving treatment landscape for CSCC.
Review in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Squamous Cell Carcinoma of the Nail Unit: A Comprehensive Review of Clinical Features, Diagnostic Workflow, Management Strategies and Therapeutic Options.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment landscape for cutaneous squamous cell carcinoma (CSCC) is evolving, with immunotherapy transforming care across all stages of disease and expanding the role of dermatologists. While surgery and radiotherapy remain cornerstones for localized CSCC, immune checkpoint inhibitors (ICIs) offer durable responses and survival benefits in advanced cases. Emerging approaches, including neoadjuvant, adjuvant, and intralesional ICIs, provide dermatologists with opportunities to integrate these therapies into practice, potentially enhancing surgical outcomes and preserving function in high-risk, resectable CSCC. Preliminary data on anti-PD-1 therapy as a preventive strategy for actinic neoplasia syndrome introduces new avenues for long-term management, though further evidence is needed. As systemic immunotherapy becomes increasingly relevant in dermatology, addressing immunotherapy-related adverse events requires interdisciplinary collaboration and specialized training. These advancements emphasize the expanding responsibilities of dermatologists in CSCC management while highlighting the importance of continued research and thoughtful application of these therapies.
Indexed as
Identifiers
40009258What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.